These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 29040195)

  • 21. Grading by the Ki-67 Labeling Index of Endoscopic Ultrasound-Guided Fine Needle Aspiration Biopsy Specimens of Pancreatic Neuroendocrine Tumors Can Be Underestimated.
    Hwang HS; Kim Y; An S; Kim SJ; Kim JY; Kim SY; Hwang DW; Park DH; Lee SS; Kim SC; Seo DW; Hong SM
    Pancreas; 2018; 47(10):1296-1303. PubMed ID: 30211805
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evaluation of Ki-67 index in EUS-FNA specimens for the assessment of malignancy risk in pancreatic neuroendocrine tumors.
    Hasegawa T; Yamao K; Hijioka S; Bhatia V; Mizuno N; Hara K; Imaoka H; Niwa Y; Tajika M; Kondo S; Tanaka T; Shimizu Y; Kinoshita T; Kohsaki T; Nishimori I; Iwasaki S; Saibara T; Hosoda W; Yatabe Y
    Endoscopy; 2014 Jan; 46(1):32-8. PubMed ID: 24218309
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pathologic Considerations in Gastroenteropancreatic Neuroendocrine Tumors.
    Bellizzi AM
    Surg Oncol Clin N Am; 2020 Apr; 29(2):185-208. PubMed ID: 32151355
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Phosphohistone H3 and Ki-67 labeling indices in cytologic specimens from well-differentiated neuroendocrine tumors of the gastrointestinal tract and pancreas: a comparative analysis using automated image cytometry.
    Fung AD; Cohen C; Kavuri S; Lawson D; Gao X; Reid MD
    Acta Cytol; 2013; 57(5):501-8. PubMed ID: 24021213
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Phosphorylated Histone H3 (PHH3) Is a Superior Proliferation Marker for Prognosis of Pancreatic Neuroendocrine Tumors.
    Villani V; Mahadevan KK; Ligorio M; Fernández-Del Castillo C; Ting DT; Sabbatino F; Zhang I; Vangel M; Ferrone S; Warshaw AL; Lillemoe KD; Wargo J; Deshpande V; Ferrone CR
    Ann Surg Oncol; 2016 Dec; 23(Suppl 5):609-617. PubMed ID: 27020585
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Recent updates on grading and classification of neuroendocrine tumors.
    Kim JY; Hong SM; Ro JY
    Ann Diagn Pathol; 2017 Aug; 29():11-16. PubMed ID: 28807335
    [TBL] [Abstract][Full Text] [Related]  

  • 27. APOBEC3B High Expression in Gastroenteropancreatic Neuroendocrine Neoplasms and Association With Lymph Metastasis.
    Feng C; Zheng Q; Yang Y; Xu M; Lian Y; Huang J; Jiang Y
    Appl Immunohistochem Mol Morphol; 2019 Sep; 27(8):599-605. PubMed ID: 30095460
    [TBL] [Abstract][Full Text] [Related]  

  • 28. High VEGF serum values are associated with locoregional spread of gastroenteropancreatic neuroendocrine tumors (GEP-NETs).
    Cigrovski Berković M; Čačev T; Catela Ivković T; Marout J; Ulamec M; Zjačić-Rotkvić V; Kapitanović S
    Mol Cell Endocrinol; 2016 Apr; 425():61-8. PubMed ID: 26805636
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of Monitor-Image and Printout-Image Methods in Ki-67 Scoring of Gastroenteropancreatic Neuroendocrine Tumors.
    Dogukan FM; Yilmaz Ozguven B; Dogukan R; Kabukcuoglu F
    Endocr Pathol; 2019 Mar; 30(1):17-23. PubMed ID: 30367334
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Role of PD-L1 expression as a biomarker for GEP neuroendocrine neoplasm grading.
    Cavalcanti E; Armentano R; Valentini AM; Chieppa M; Caruso ML
    Cell Death Dis; 2017 Aug; 8(8):e3004. PubMed ID: 28837143
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Are G3 ENETS neuroendocrine neoplasms heterogeneous?
    Vélayoudom-Céphise FL; Duvillard P; Foucan L; Hadoux J; Chougnet CN; Leboulleux S; Malka D; Guigay J; Goere D; Debaere T; Caramella C; Schlumberger M; Planchard D; Elias D; Ducreux M; Scoazec JY; Baudin E
    Endocr Relat Cancer; 2013 Oct; 20(5):649-57. PubMed ID: 23845449
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Accuracy of visual assessments of proliferation indices in gastroenteropancreatic neuroendocrine tumours.
    Young HT; Carr NJ; Green B; Tilley C; Bhargava V; Pearce N
    J Clin Pathol; 2013 Aug; 66(8):700-4. PubMed ID: 23703851
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Sporadic Gastric Well-Differentiated Neuroendocrine Tumors Have a Higher Ki-67 Proliferative Index.
    Lee HE; Mounajjed T; Erickson LA; Wu TT
    Endocr Pathol; 2016 Sep; 27(3):259-67. PubMed ID: 27306997
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Well-differentiated gastroenteropancreatic G3 NET: findings from a large single centre cohort.
    Lithgow K; Venkataraman H; Hughes S; Shah H; Kemp-Blake J; Vickrage S; Smith S; Humphries S; Elshafie M; Taniere P; Diaz-Cano S; Dasari BVM; Almond M; Ford S; Ayuk J; Shetty S; Shah T; Geh I
    Sci Rep; 2021 Sep; 11(1):17947. PubMed ID: 34504148
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The high-grade (WHO G3) pancreatic neuroendocrine tumor category is morphologically and biologically heterogenous and includes both well differentiated and poorly differentiated neoplasms.
    Basturk O; Yang Z; Tang LH; Hruban RH; Adsay V; McCall CM; Krasinskas AM; Jang KT; Frankel WL; Balci S; Sigel C; Klimstra DS
    Am J Surg Pathol; 2015 May; 39(5):683-90. PubMed ID: 25723112
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Gastroenteropancreatic Well-Differentiated Grade 3 Neuroendocrine Tumors: Review and Position Statement.
    Coriat R; Walter T; Terris B; Couvelard A; Ruszniewski P
    Oncologist; 2016 Oct; 21(10):1191-1199. PubMed ID: 27401895
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Correlation between grade and prognosis in metastatic gastroenteropancreatic neuroendocrine tumors.
    Strosberg J; Nasir A; Coppola D; Wick M; Kvols L
    Hum Pathol; 2009 Sep; 40(9):1262-8. PubMed ID: 19368957
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prognostic factors for gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs): what's better?
    Milione M
    Endocrine; 2018 Jan; 59(1):1-3. PubMed ID: 28417314
    [No Abstract]   [Full Text] [Related]  

  • 39. Comparison of methods for proliferative index analysis for grading pancreatic well-differentiated neuroendocrine tumors.
    Goodell PP; Krasinskas AM; Davison JM; Hartman DJ
    Am J Clin Pathol; 2012 Apr; 137(4):576-82. PubMed ID: 22431534
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Neuroendocrine tumors involving the gastroenteropancreatic tract: a clinicopathological evaluation of 773 cases.
    Estrozi B; Bacchi CE
    Clinics (Sao Paulo); 2011; 66(10):1671-5. PubMed ID: 22012036
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.